ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > So.far.only fda

<< Previous

Bullboard Posts

Next >>

Comment by goldtechon Jun 08, 2021 3:21pm

116 Views

Post# 33349173

RE:RE:RE:So.far.only fda

You got that right M101 , people ask why does the shares not go further then a few pennies. Elliott and Gene diluted this company so much that it will take institutions to take down millions of shares. Now you know why you should withhold votes for all the standing Directors except for Dr.Cashman. The rest of those bums voted in favour of massive dilution and are worthless .We need news with meat on the bone and Gene does not know how to do a deal.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China